menu search

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck ...

October 22, 2023, 10:01 am

Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023

– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial ...

October 22, 2023, 8:25 am

Revolution medicines presents promising clinical activity and safety data from phase 1/1b trial of rmc-6236

Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) — Revolution Medicine...

October 22, 2023, 6:30 am

Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...

October 21, 2023, 3:31 pm

Precede biosciences unveils groundbreaking clinical data for its pioneering liquid biopsy platform at esmo 2023 and simultaneously publishes in nature medicine

Pivotal findings stem from Precede’s first-in-class platform in collaboration with Dana-Farber cancer...

October 21, 2023, 8:25 am

Xencor: a mid-stage clinical company with falling losses

Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medica...

October 20, 2023, 11:02 pm

Nfl head coach pledges to pay forward support he received when facing cancer diagnosis

Washington Commanders’ Ron Rivera Recognized with the cancer Support Community’s Founders Award for...

October 20, 2023, 6:41 pm

Trending tickers: at&t, merck-daiichi sankyo, klaviyo: trending tickers october 29, 2023

Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japan...

October 20, 2023, 5:44 pm

Merck (mrk) inks deal with daiichi to develop cancer drugs

Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of ...

October 20, 2023, 2:17 pm

: merck’s keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

Merck & Co. MRK said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab...

October 20, 2023, 12:13 pm

Dow jones newswires: daiichi sankyo shares jump on multibillion-dollar drug development deal with merck

Daiichi Sankyo shares rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck to jointly develop and commercialize t...

October 20, 2023, 8:59 am

Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus tra...

October 20, 2023, 8:13 am

Bristol myers' (bmy) opdivo sc meets kidney cancer study goals

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kid...

October 20, 2023, 6:46 am

Daiichi sankyo shares jump on multibillion-dollar drug development deal with merck

Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly d...

October 19, 2023, 10:40 pm


Search within

Pages Search Results: